Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian Influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV)

Virology Journal

Volumn 6, Issue , 2009, Pages

  Pleschka, Stephan ^a   Stein, Michael ^a   Schoop, Roland ^b   Hudson, James B ^c  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Bioforce AG   (Switzerland)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ECHINACEA PURPUREA EXTRACT; ECHINAFORCE; OSELTAMIVIR; RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; PLANT EXTRACT;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN; CULTURE MEDIUM; DRUG MECHANISM; DRUG SYNTHESIS; ECHINACEA PURPUREA; HEMAGGLUTINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N7; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PANDEMIC; RECEPTOR BINDING; VIRUS ENTRY; VIRUS INACTIVATION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TITRATION; ANIMAL; CELL LINE; CHEMISTRY; DOG; DRUG EFFECT; ECHINACEA; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; VIRUS ATTACHMENT;

ANIMALIA; AVES; AVIAN INFLUENZA VIRUS; ECHINACEA PURPUREA; ORTHOMYXOVIRIDAE; SUIDAE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; ECHINACEA; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H7N7 SUBTYPE; MICROBIAL SENSITIVITY TESTS; PLANT EXTRACTS; VIRUS ATTACHMENT;

EID: 72449195360     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-6-197     Document Type: Article

References (29)

1. On the epidemiology of influenza. JJ Cannell M Zasloff CF Garland R Scragg E Giovannucci, Virology J 2008 5 29 10.1186/1743-422X-5-29
2. Novel swine-origin influenza A virus in humans: another pandemic knocking at the door. M Michaelis HW Doerr J Cinatl, Med Microbiol Immunol 2009 198 175 183 10.1007/s00430-009-0118-5 19543913
3. Emergence and pandemic potential of swine-origin H1N1 influenza virus. G Neumann T Noda Y Kawaoka, Nature 2009 459 931 939 10.1038/nature08157 19525932
4. Avian influenza: The tip of the iceberg. H Bahlky, Ann Thorac Med 2009 3 154 157
5. The Highly Pathogenic Avian Influenza H5N1-Initial Molecular Signals for the Next Influenza Pandemic. Y Suzuki, Chang Gung Med J 2009 32 258 263 19527604
6. Developing New Antiviral Agents for Influenza Treatment: What does the Future Hold? F Hayden, Clin Infec Dis 2009 48 3 S13 10.1086/591851
7. Inactivated influenza vaccines: methods, policies, and politics. T Jefferson C Di Pietrantonj MG Debalini A Rivetti V Demicheli, J Clin Epidemiol 2009 62 677 686 10.1016/j.jclinepi.2008.07.001 19124222
8. The potential impact of neuraminidase inhibitor resistant influenza. A Lackenby CI Thompson J Democratis, Curr Op Infec Dis 2008 21 626 638 10.1097/QCO.0b013e3283199797
9. Oseltamivir- and Amantadine-Resistant Influenza viruses A (H1N1). PKC Cheng TWC Leung ECM Ho PKC Leung AYY Ng MYY Lai WWL Lim, Emerg Infec Dis 2009 15 966 968 10.3201/eid1506.081357
10. Influenza-virus-induced signaling cascades: targets for antiviral therapy? S Ludwig O Planz S Pleschka T Wolff, Trends Mol Med 2003 9 46 52 10.1016/S1471-4914(02)00010-2 12615037
11. Targeting cell signaling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. S Ludwig, J Antimic Ther 2009 64 1 4 10.1093/jac/dkp161
12. Influenza virus propagation is impaired upon specific inhibition of the Raf/MEK/ERK signaling cascade. S Pleschka T Wolff C Ehrhardt G Hobom O Planz UR Rapp S Ludwig, Nat Cell Biol 2001 3 301 305 10.1038/35060098 11231581
13. MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. S Ludwig T Wolff C Ehrhardt WJ Wurzer J Reinhardt O Planz S Pleschka, FEBS Lett 2004 561 37 43 10.1016/S0014-5793(04)00108-5 15013748
14. NF-kappaB-dependent of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation. WJ Wurzer C Erhardt S Pleschka F Berberich-Seibelt T Wolff H Walczak O Planz S Ludwig, J Biol Chem 2004 279 30931 30937 10.1074/jbc. M403258200 15143063
15. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. I Mazur WJ Wurzer C Ehrhardt S Pleschka P Puthavathana T Silberzahn T Wolff O Planz S Ludwig, Cell Microbiol 2007 9 1683 94 10.1111/j.1462-5822.2007.00902.x 17324159
16. Inhibition of Influenza Virus Replication by Resveratrol. AT Palamara L Nencioni K Aquilano G De Chiara L Hernandez F Cozzolino MR Ciriolo E Garaci, J Infec Dis 2005 191 1719 1729 10.1086/429694 (Pubitemid 40656761)
17. Anti-influenza Agents from Plants and Traditional Chinese Medicine. X Wang W Jia A Zhao X Wang, Phytother Res 20 335 341 10.1002/ptr.1892 16619359
18. A Polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. C Ehrhardt ER Hrincius V Korte I Mazur K Droebner A Poetter S Dreschers M Schmolke O Planz S Ludwig, Antivir Res 2007 76 38 47 10.1016/j.antiviral.2007.05.002 17572513
19. CYSTUS052, a polyphenol-rich plant extract, exerts anti-influenza virus activity in mice. K Droebner C Ehrhardt A Poetter S Ludwig O Planz, Antivir Res 2007 76 1 10 10.1016/j.antiviral.2007.04.001 17573133
20. Phytomedicines as antivirals. JB Hudson GHN Towers, Drugs of the Future 1999 24 295 320 10.1358/dof.1999.024.03.858620 (Pubitemid 29214210)
21. Induction of pro-inflammatory cytokines by respiratory viruses and reversal by standardized Echinacea, a potent antiviral herbal extract. M Sharma SA Anderson R Schoop JB Hudson, Antiviral Res 2009 83 165 170 10.1016/j.antiviral.2009.04.009 19409931
22. Echinacea Extracts Contain Significant and Selective Activities Against Human Pathogenic Bacteria. M Sharma S Vohra JT Arnason JB Hudson, Pharmac Biol 2008 46 111 116 10.1080/13880200701734919 (Pubitemid 351196232)
23. Selection of Natural Health Products for Clinical Trials: a Preclinical Template. S Vohra D Adams JB Hudson JA Moore S Vimalanathan M Sharma A Burt E Lamont N Lacaze JT Arnason TD Lee, Can J Physiol Pharmacol 2009 87 371 378 10.1139/Y09-021 19448735
24. Characterization of antiviral activities in Echinacea root preparations. J Hudson S Vimalanathan L Kang V Treyvaud Amiguet J Livesey JT Arnason, Pharmac Biol 2005 43 790 796 10.1080/13880200500408491 (Pubitemid 43336370)
25. Echinacea purpurea aerial parts contain multiple antiviral compounds. S Vimalanathan L Kang V Treyvaud Amiguet J Livesey JT Arnason J Hudson, Pharmac Biol 2005 43 740 745 10.1080/13880200500406354 (Pubitemid 43336361)
26. Anti-inflammatory activities of Echinacea extracts do not correlate with traditional marker components. S Vimalanathan JT Arnason JB Hudson, Pharmac Biol 2009 47 430 435 10.1080/13880200902800204
27. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. AC Hurt, et al. Antivir Res 2009 83 90 93 10.1016/j.antiviral.2009.03.003 19501261
28. Oseltamivir-Resistant Novel Influenza A (H1N1) Virus Infection in Two Immunosuppressed Patients-Seattle Washington. Morbidity Mortality Weekly Report, MMWR 2009 58 32 893 896 19696719
29. Echinacea species (Echinacea angustifolia (DC.) Hell. Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench: a review of their chemistry, pharmacology and clinical properties. J Barnes LA Anderson S Gibbons JD Phillipson, J Pharm Pharmacol 2005 57 929 954 10.1211/0022357056127 16102249